American Kidney Fund
Sign Up or Sign In

Blog  |  En Español  |  Partners |  Contact Us | HelpLine |  AKF Store
 text size Text Size OneText Size TwoText Size Three

Bookmark and Share

Advocate for Kidney Patients


The American Kidney Fund advocates for policies to improve the health of millions of Americans and their families who are living with, or are at risk of developing, kidney disease.

Join AKF's Growing Advocacy Network!



Take Action


Take Action: Support Funding for Kidney Research

Join us in urging members of Congress to support increased funding for kidney disease research at the National Institutes of Health. More individuals are affected by chronic kidney disease (CKD) than by cancer or heart disease, yet CKD is underfunded compared to the research dollars invested in these and other diseases. Take action today!

AKF Advocate Spotlight

The American Kidney Fund highlights members of our Advocacy Network who are working to increase awareness of kidney disease in their community.

Stephanie Shabanowitz - June 2014

Stephanie Shabanowitz

Stephanie Shabanowitz from Oakdale, Conn., is passionate about educating others about pediatric kidney disease and discussing important policy issues with Congressional representatives. Read more >>



Your Voice is Powerful! CMS Drops Proposal to Restrict Access to Immunosuppressive Drugs

Today, the Centers for Medicare & Medicaid Services (CMS) said it will drop its recent proposal to remove immunosuppressive drugs from “protected class” status under Medicare Part D. This means that transplant patients will continue to have access under Part D for all approved immunosuppressive drugs.

In a letter to Congressman Henry Waxman, Ranking Member of the House Energy and Commerce Committee, CMS Administrator Marilyn Tavenner said the agency “received numerous concerns about some elements of the proposal from members of Congress and stakeholders.” The agency will continue to gather and evaluate stakeholder input, and may revisit the issue in future years.

This is a victory for the entire kidney community and the patients we serve.  Over the past several months, AKF and many other patient advocacy organizations have participated in meetings with the Obama administration and key Congressional staff to communicate the impact the rule would have on transplant patients’ access to immunosuppressive drugs.  AKF also submitted comments expressing our opposition to the rule, and more than 700 members of AKF’s Advocacy Network contacted their Congressional representatives on this issue.

We are grateful to every individual who joined with us in reaching out to Congress and CMS on this issue. Together, we have made a difference. Moving forward, we will continue to work with CMS to ensure that transplant recipients retain access to all immunosuppressive drugs under Medicare Part D. 



Watch AKF’s Advocacy Video



Meet AKF Advocate and Hero of Hope NeShell Monroe

At The Hope Affair, the American Kidney Fund's national gala, NeShell Monroe was honored as the 2013 Hero of Hope. NeShell works tirelessly to encourage and empower other patients at her dialysis facility to care for themselves and to live their lives to the fullest. She reaches out to the community at local health events and through the media to educate people about kidney disease and its leading causes, the importance of early detection, and how to prevent kidney disease. NeShell has traveled to Washington, D.C., to meet with legislators and help them understand how their policy decisions affect kidney patients.



CMS Releases Final Rule on ESRD Payments

On November 22, 2013, the Centers for Medicare & Medicaid Services (CMS) released its final rule  that will result in a 12 percent cut in Medicare dialysis payments for people who have end-stage renal disease (ESRD).

The American Kidney Fund advocated against these cuts as we believe they will have negative consequences on ESRD patients’ access to quality care and services. In addition, over 1,000 letters were sent to members of Congress from our Advocates expressing concern with the proposed cuts.

According to the final rule, payments will remain the same for 2014 and 2015; however, the full $30 cut per treatment will be phased in over the next 3-4 years. AKF remains concerned that this cut may limit ESRD patients’ treatment options and, although the phase-in is a less drastic approach, it will not mitigate the potential for challenges regarding access to quality care in the future. Since 2011, the Medicare ESRD program has undergone a series of significant payment reforms and reductions so we will be closely monitoring how these sequential cuts will impact patient care.  Read AKF’s statement regarding the rule.

GMS Login
Give Online
Join Us at Kidney Action Day
Register for the Virtual Walk
Stay Connected

Putting Your Contributions to Work

Wellsphere Health Impact AwardAIP Rated A+ CharityCharity Navigator Better Business Bureau LogoNational Health Council Standards of Excellence
Consumers Digest Top Charity
Consumers Digest
4-Star Charity (12th consecutive year)
Charity Navigator

Stay Connected With the American Kidney Fund:

American Kidney Fund on Facebook   American Kidney Fund on Twitter   American Kidney Fund on YouTube